newsfilter
← Latest News
GlobeNewswire·

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

- THETIS Cohort B enrollment follows positive Independent Data Safety Monitoring Committee review - - Monotherapy data from higher-dose cohorts in both CHIRON and THETIS and combination data from THETIS Cohort B expected in 2H 2022 - LONDON, May 0